COLORADO SPRINGS, CO - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today acknowledges and is very excited about the Landmark move with the Drug Enforcement Agency's (DEA) decision to review marijuana's federal drug classification as early as mid-2016.
Rescheduling marijuana would ease restrictions on research across the country, while at the same time reducing penalties for marijuana offenses. Increased research capabilities could spur innovation and growth in the cannabis industry.
In a letter to the Senators; http://big.assets.huffingtonpost.com/dearesponse.pdf the Drug Enforcement Administration (DEA) is looking to decide on the reclassification of Marijuana by mid-year.
For years, marijuana has shared the "Schedule I" classification with heroin and LSD, drugs with much higher rates of death and hospitalization for users. This classification also specifies the drug has no "current accepted medical use". Cannabis Science, along with the masses, believe this has changed emphatically, based on the many ground-breaking university and private studies along with the ever growing long list of peer reviewed articles.
"We are very pleased to hear the DEA's decision to review marijuana's drug classification scheduling. It is clear to us and to so many others that the natural drug offers a host of health benefits and treatment properties. Cannabis Science will benefit extraordinarily as our research is already on the cutting edge, this Landmark move will open the industry in leaps and bounds," said Cannabis Science Inc. President, CEO & Co-Founder Raymond C. Dabney.
The DEA hopes to publish its decision in the first half of 2016. This decision is becoming increasingly important as more states decide to legalize cannabis for medicinal use. Nearly half of the U.S. states have already made such a decision, and a schedule change would have positive benefits for each of them.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.
Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934.
A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Some or all of the events or results anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs.
Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements.
Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors.
Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
No comments:
Post a Comment